Infrrd Announces the Official Launch of Ally: The First Agentic AI Workforce for Mortgage Auditing
SAN JOSE, Calif.–(BUSINESS WIRE)–#agenticAI—Infrrd, a global leader in AI-driven document processing solutions, has announced the official launch... Read more.
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – OSAKA, Japan & WALTHAM, Mass.–(BUSINESS... Read more.
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma... Read more.
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including... Read more.
Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress
5 confirmed partial responses (PRs) among 13 evaluable non-small cell lung cancer (NSCLC) patients (ORR 38%); 1 confirmed PR among 7 breast cancer patients Favorable... Read more.
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
– CABOMETYX reduced the risk of disease progression or death by 81% versus placebo in patients with advanced lung or thymic neuroendocrine tumors (NET) – –... Read more.
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
– Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK... Read more.
CORRECTING and REPLACING Alliant Insurance Services Expands Transportation Risk and Cross-Border Expertise in Texas through Strategic Acquisition and Key Hires
Alliant hires Nader Dabboussi and Jordan Lewis to execute cross-border strategy and secure foothold in one of U.S.’s busiest international trade ports IRVINE,... Read more.
Light & Wonder Statement on NV Legal Proceedings
LAS VEGAS–(BUSINESS WIRE)–Light & Wonder, Inc. (NASDAQ and ASX: LNW) (“Light & Wonder,” “L&W,” “we” or the “Company”) is... Read more.
Typhoon Recovery: U-Haul Offers 30 Days Free Storage across Alaska
ANCHORAGE, Alaska–(BUSINESS WIRE)–#30daysfree–U-Haul® Company of Alaska has made all of its 11 Company facilities across the state available to... Read more.